Stanford BMT - CCT Oral presentations at ASH 2020:

129 Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma: Sham Mailankody, MBBS¹, Jeffrey V. Matous, MD², Michaela Liedtke, MD³, Surbhi Sidana, MD⁴, Shahbaz Malik, MD^5*, Rajneesh Nath, MD⁶, Olalekan O. Oluwole, MBBS, MPH⁷, Erin E. Karski^8*, Wade Lovelace^8*, Xiangdong Zhou, PhD^8*, Srinand Nandakumar, PhD^8*, Arun Balakumaran, MD, PhD⁸ and Parameswaran Hari, MD, MRCP⁹

199 Profiling T-Cell Receptor Diversity and Dynamics during Lymphoma Immunotherapy Using Cell-Free DNA (cfDNA): Navika D Shukla^1*, Alexander F. M. Craig, MPhil², Brian Sworder, MD, PhD¹, David M. Kurtz, MD, PhD¹, Charles Macaulay, MSc, BA^3*, Andrea Garofalo, BS, BA^1*, Matthew J. Frank, MD, PhD⁴, Stefan Alig, MD^1*, George Duran, BA^5*, Youn H. Kim, MD⁶, James Zehnder, MD⁷, Crystal L. Mackall, MD⁸, David B. Miklos, MD, PhD⁴, Maximilian Diehn, MD, PhD^9*, Michael S. Khodadoust, MD, PhD¹⁰ and Ash A. Alizadeh, MD, PhD¹¹

310 - Disparities in the Use of Allogeneic Hematopoietic Stem Cell Transplant Among Children, Adolescents, and Young Adults with Acute Leukemia in California: Lena E. Winestone, MD, MSHP^1,2, Qian Li, MS^3*, Lori S. Muffly, MD, MS⁴, Kelly D Getz^5*, Elysia Alvarez, MD, MPH^3*, Ted Wun, MD³ and Theresa Keegan, PhD, MS³

353 - Belumosudil for Chronic Graft-Versus-Host Disease (cGVHD) after 2 or More Prior Lines of Therapy: The Rockstar Study (KD025-213): Corey Cutler, MD, MPH, FRCPC¹, Stephanie J. Lee, MD, MPH², Sally Arai, MD, MS³, Marcello Rotta, MD⁴, Behyar Zoghi, MD^5*, Aravind Ramakrishnan, MD⁶, David Eiznhamer, PhD^7*, Olivier Schueller, PhD^8*, Zhongming Yang, PhD^9*, Laurie S. Green, MEd^10*, Sanjay K. Aggarwal, MD^8*, Bruce R. Blazar, MD¹¹, Steven Z. Pavletic, MD, MS¹² and Madan Jagasia, MBBS, MS, MMHC¹³

354 Orca-T, a Precision Treg-Engineered Donor Product, Prevents Acute Gvhd with Less Immunosuppression in an Early Multicenter Experience with Myeloablative HLA-Matched Transplants: Everett H Meyer, MD, PhD^1*, Rasmus Hoeg, MD^2*, Anna Moroz, MD, PhD^3*, Bryan Xei, BS^4*, Hsin-Hsu Wu, MD^5*, Rahul Pawar^5*, Kartoosh Heydari, MD^5*, David B. Miklos, MD, PhD¹, Parveen Shiraz, MD¹, Lori S. Muffly, MD, MS⁶, Sally Arai, MD, MS¹, Laura J. Johnston, MD¹, Robert Lowsky, MD, FRCP¹, Andrew R. Rezvani, MD¹, Judith A Shizuru, MD, PhD¹, Wen-Kai Weng, MD, PhD⁷, Nathaniel Fernhoff, PhD^8*, Gerhard Bauer^9*, Arpita Gandhi, MD, MS^10*, Amy Putnam^8*, J. Scott Scott McClellan, MD, PhD¹¹, Bronwen E. Shaw, PhD, MRCP, FRCPath¹², Joseph P. McGuirk, DO¹³, Mehrdad Abedi, MD¹⁴ and Robert S. Negrin, MD¹

556 - CD58 Aberrations Limit Durable Responses to CD19 CAR in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel but Can be Overcome through Novel CAR Engineering: Robbie G. Majzner, MD¹, Matthew J. Frank, MD, PhD², Christopher Mount, MD, PHD^3*, Aidan Tousley^3*, David M. Kurtz, MD, PhD⁴, Brian Sworder, MD, PhD⁵, Katherine A Murphy^6*, Antigoni Manousopoulou^7*, Kennedy Kohler^3*, Maria Caterina Rotiroti, PhD^3*, Jay Y. Spiegel, MD, FRCPC², Yasodha Natkunam, MD, PhD⁸, Sheren F. Younes, MD, PhD^9*, Elena Sotillo, PhD^1*, Vandon Duong^3*, Charles Macaulay, MSc, BA^10*, Zinaida Good, PhD¹¹, Peng Xu, MD^3*, Louai Labanieh^1*, Leo D Wang, MD, PhD¹², Ash A. Alizadeh, MD, PhD⁴, Michelle Monje, MD, PHD^3*, David B. Miklos, MD, PhD² and Crystal L. Mackall, MD¹¹

622 - Treatment Patterns, Type of Front-Line Regimen, and Outcomes Among Older Adults with Acute Myeloid Leukemia: A Population-Based Analysis in the Modern Era: Vanessa E Kennedy, MD¹, Theresa Keegan, PhD, MS2, Qian Li, MS3*, Fran Maguire, PhD, MPH4* and Lori S. Muffly, MD, MS5

495 Survival Following Post-HCT Relapse in Adult Acute Lymphoblastic Leukemia Has Improved in the Era of Novel Immunotherapies: A Single Institution Analysis: Juliana Craig, BA^1*, Maria Iglesias, BS^1*, Kristen Cunanan, PhD^2*, Sally Arai, MD, MS³, Matthew J. Frank, MD, PhD³, Laura J. Johnston, MD³, Robert Lowsky, MD, FRCP³, Everett H Meyer, MD, PhD^3*, David B. Miklos, MD, PhD³, Robert S. Negrin, MD³, Andrew R. Rezvani, MD³, Judith A Shizuru, MD, PhD³, Surbhi Sidana, MD⁴, W-K Weng, MD, PhD⁵, Parveen Shiraz, MD³ and Lori S. Muffly, MD, MS⁶

736 - CD22-Directed CAR T-Cell Therapy Mediates Durable Complete Responses in Adults with Relapsed or Refractory Large B-Cell Lymphoma after Failure of CD19-Directed CAR T-Cell Therapy and High Response Rates in Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: John H. Baird, MD^1,2, Matthew J. Frank, MD, PhD^1,2, Juliana Craig, BA^1*, Shabnum Patel, PhD^3*, Jay Y. Spiegel, MD, FRCPC^1,2, Bita Sahaf, PhD^1*, Sheren F. Younes, MD, PhD^4*, Jean S. Oak, MD, PhD^5*, Yasodha Natkunam, MD, PhD⁵, Zachary Ehlinger, MS^3*, Warren D. Reynolds, BS^3*, Sally Arai, MD, MS², Laura J. Johnston, MD², Robert Lowsky, MD, FRCP², Robert S. Negrin, MD⁶, Andrew R. Rezvani, MD², Parveen Shiraz, MD^2,3, Surbhi Sidana, MD^3,6, Wen-Kai Weng, MD, PhD², Liora M. Schultz, MD⁷, Sneha Ramakrishna, MD⁸, Kara L Davis, DO⁹, Steven A. Feldman, PhD^3*, Crystal L. Mackall, MD^1,10, David B. Miklos, MD, PhD^2,11 and Lori S. Muffly, MD, MS^1,12

Stanford BMT - CCT Poster Abstracts:

1034 Routine Use of Gemtuzumab Ozogamicin in 7+3-Based Inductions for All “Non-Adverse” Risk AML: Gavin Hui, MD^1*, Abdullah Ladha, MD^2*, Edna Cheung, PharmD^3*, Caroline Berube, MD⁴, Steven Coutre, MD⁴, Jason Gotlib, MD, MS⁴, Michaela Liedtke, MD⁴, Tian Y Zhang, MD, PhD⁴, Lori S. Muffly, MD, MS² and Gabriel N. Mannis, MD⁴

1507 Outcomes after Autologous Stem Cell Transplant in Patients with Relapsed Multiple Myeloma: Christopher Lemieux, MD¹, Juliana Craig, BA^1*, David Iberri, MD¹, Sally Arai, MD, MS¹, Laura J. Johnston, MD¹, Robert Lowsky, MD, FRCP¹, Lori S. Muffly, MD, MS¹, Parveen Shiraz, MD¹, Michaela Liedtke, MD², Andrew R. Rezvani, MD¹, Matthew J. Frank, MD, PhD¹, Wen-Kai Weng, MD, PhD¹, Everett H Meyer, MD, PhD^1*, Judith A Shizuru, MD, PhD¹, Robert S. Negrin, MD¹, David B. Miklos, MD, PhD¹ and Surbhi Sidana, MD¹

1788 Bleeding and Thrombosis Are Associated with Endothelial Dysfunction in CAR-T Cell Therapy and Are Increased in Patients Experiencing Neurologic Toxicity: Andrew Johnsrud, MD¹, Juliana Craig, BA^1*, John H. Baird, MD^1,2, Jay Y. Spiegel, MD, FRCPC¹, Lori S. Muffly, MD, MS³, James Zehnder, MD⁴, Robert S. Negrin, MD¹, Laura J. Johnston, MD¹, Sally Arai, MD, MS¹, Judith A Shizuru, MD, PhD¹, Robert Lowsky, MD, FRCP¹, Everett H Meyer, MD, PhD^1*, Wen-Kai Weng, MD, PhD¹, Parveen Shiraz, MD¹, Andrew R. Rezvani, MD¹, Theresa Latchford, RN^1*, Crystal L. Mackall, MD⁵, David B. Miklos, MD, PhD¹, Matthew J. Frank, MD, PhD¹ and Surbhi Sidana, MD⁶

3255 - Molecular Imaging of Chimeric Antigen Receptor T Cells By ICOS-Immunopet: Federico Simonetta, MD, PhD^1*, Israt S. Alam, PhD^2*, Juliane K. Lohmeyer, MD^1*, Bita Sahaf, PhD^3*, Zinaida Good, PhD³, Weiyu Chen, PhD^4*, Zunyu Xiao, MD, PhD^4*, Toshihito Hirai, MD, PhD^1,5*, Lukas Scheller, MD^6*, Pujan Engels, M.Sc.^6*, Ophir Vermesh, MD, PhD^2*, Elise Robinson^7*, Tom Haywood, PhD^7*, Ataya Sathirachindra^7*, Jeanette Baker^1*, Meena B. Malipatlolla^8*, Liora M. Schultz, MD⁹, Jay Y. Spiegel, MD, FRCPC¹⁰, Jason T. Lee, PhD^11*, David B. Miklos, MD, PhD¹⁰, Crystal L. Mackall, MD^3,12, Sanjiv S. Gambhir, MD, PhD^2* and Robert S. Negrin, MD1⁰

1144 Intratumoral CpG, Local Radiation, and Oral Ibrutinib Combine to Produce Effective in Situ Vaccination in Patients with Low-Grade B-Cell Lymphoma: Tanaya Shree, MD, PhD, BA¹, Michael S. Khodadoust, MD, PhD², Debra K. Czerwinski, BA¹, Matthew J. Frank, MD, PhD³, Sara Beygi, MD^4*, Steven R. Long, MD^5*, Brock Martin, MD^6* and Ronald Levy, MD

1457 First Report of Non-Genotoxic Conditioning with JSP191 (anti-CD117) and Hematopoietic Stem Cell Transplantation in a Newly Diagnosed Patient with Severe Combined Immune Deficiency: Rajni Agarwal, MD¹, Kenneth I. Weinberg, MD², Hye-Sook Kwon, PhD^3*, Anne Le^3*, Janel R Long-Boyle, PharmD, PhD^4,5*, Donald B. Kohn, MD⁶, Kathryn Bradford, MD^7*, Satiro De Oliveira, MD^7*, Alice Bertaina, MD, PhD¹, Agnieszka Czechowicz, MD, PhD¹, Matt Porteus, MD, PhD¹, David C Shyr, MD^1*, Katja G Weinacht, MD, PhD^1*, Ami J Shah, MD¹, Melissa Mavers, MD, PhD¹, Elisabeth Merkel, RN^1*, Janice W Brown, MD³, Christopher C. Dvorak, MD⁴, Robertson Parkman, MD¹, Maria Grazia Roncarolo, MD¹ and Judith A Shizuru, MD, PhD^1,8

3322 - Outcomes after Second Allogeneic Transplantation and Donor Lymphocyte Infusion for Relapse after a First Allogeneic Transplant: Christopher Lemieux, MD, Lori S. Muffly, MD, MS, Sally Arai, MD, MS, Andrew R. Rezvani, MD, Surbhi Sidana, MD, Laura J. Johnston, MD, Wen-Kai Weng, MD, PhD, Parveen Shiraz, MD, Matthew J. Frank, MD, PhD, Everett H Meyer, MD, PhD*, Judith A Shizuru, MD, PhD, David B. Miklos, MD, PhD, Robert S. Negrin, MD and Robert Lowsky, MD, FRCP

3332 Long-Term Outcomes of Patients with Peripheral T-Cell Lymphoma after Autologous Hematopoietic Cell Transplantation: Olivier Veilleux, MD^1*, Francisco Socola, MD¹, Sally Arai, MD, MS², Robert Lowsky, MD, FRCP², Judith A Shizuru, MD, PhD³, Parveen Shiraz, MD², Lori S. Muffly, MD, MS⁴, Laura J. Johnston, MD⁴, Matthew J. Frank, MD, PhD², Surbhi Sidana, MD¹, Everett H Meyer, MD, PhD^2*, Andrew R. Rezvani, MD², David B. Miklos, MD, PhD², Robert S. Negrin, MD⁴ and Wen-Kai Weng, MD, PhD²

975 Monitoring Measurable Residual Disease Using Peripheral Blood in Acute Lymphoblastic Leukemia: Results of a Prospective, Observational Study: Lori S. Muffly, MD, MS¹, Vandana Sundaram, MPH^2*, Connie Chen^3*, Ilana Yurkiewicz, MD, BS⁴, Eric Kuo^5*, Sarah Burnash^3*, Jay Y. Spiegel, MD, FRCPC³, Kelly Chyan^3*, Sally Arai, MD, MS³, Matthew J. Frank, MD, PhD³, Laura J. Johnston, MD³, Robert Lowsky, MD, FRCP³, Everett H Meyer, MD, PhD^3*, Robert S. Negrin, MD³, Andrew R. Rezvani, MD³, Surbhi Sidana, MD⁶, Parveen Shiraz, MD³, Judith A Shizuru, MD, PhD⁷, Wen-Kai Weng, MD, PhD³, Michaela Liedtke, MD⁸, Hyma T. Vempaty, MD⁹ and David B. Miklos, MD, PhD³

1424 5-Azacytidine Depletes Hematopoietic Stem Cells and Synergizes with an Anti-CD117 Antibody to Augment Engraftment of Donor Stem Cells in Immunocompetent Mice: Andriyana K Bankova, MD1*, Wendy W Pang, MD, PhD1, Brenda J Velasco1*, Janel R Long-Boyle, PharmD, PhD2,3* and Judith A Shizuru, MD, PhD1,4,5,6

3169 - Response Evaluation Using PET/CT in Multiple Myeloma Patients Undergoing Autologous Transplant: Tim Ellis-Caleo, MD^1*, Surbhi Sidana, MD², Michaela Liedtke, MD³ and David Iberri, MD³

1526 Hypomethylating Agents in Combination with Venetoclax As a Bridge to Allogeneic Transplant in Acute Myeloid Leukemia: Vanessa E Kennedy, MD¹, Gavin Hui, MD^2*, Daria Gaut, MD³, Varun Mittal, MD⁴, Caspian Oliai, M.D.⁵, Lori S. Muffly, MD, MS⁶, Aaron C. Logan, MD, PhD, MPhil⁷ and Gabriel N. Mannis, MD⁸

2525 Intensity of Front-Line Regimen Is Associated with Admissions, in-Hospital Days, and Discharge Destination in Older Adults with Acute Myeloid Leukemia: A Population-Based Analysis: Vanessa E Kennedy, MD¹, Theresa Keegan, PhD, MS², Qian Li, MS^3*, Fran Maguire, PhD, MPH^4* and Lori S. Muffly, MD, MS⁵

Multi-site Poster Abstracts with Stanford BMT – CCT Investigators:

3335 Maintenance Use Is More Important Than the Choice of Bortezomib-Based Triplet Induction in Newly Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplantation: Surbhi Sidana, MD¹, Shaji K. Kumar, MD², Raphael Fraser, PhD^3*, Noel Estrada-Merly, MS^4*, Maxim Norkin, MD, PhD^5*, Sergio Giralt, MD^6*, Muzaffar H. Qazilbash, MD⁷, Nina Shah, MD⁸ and Anita D'Souza, MD, MS⁹

1187 Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel):  Caron Jacobson, MD, MMSc¹, Frederick L. Locke, MD², Armin Ghobadi, MD³, David B. Miklos, MD, PhD⁴, Lazaros J. Lekakis, MD^5*, Olalekan O. Oluwole, MBBS, MPH⁶, Yi Lin, MD, PhD⁷, Ira Braunschweig, MD^8*, Brian T. Hill, MD⁹, John M. Timmerman, MD¹⁰, Abhinav Deol, MD¹¹, Patrick M. Reagan, MD¹², Patrick J. Stiff, MD¹³, Ian W. Flinn, MD, PhD¹⁴, Umar Farooq, MD¹⁵, Andre H. Goy, MD¹⁶, Peter A. McSweeney, MD^17*, Javier Munoz, MD¹⁸, Tanya Siddiqi, MD¹⁹, John M. Rossi, MS^20*, Adrian Bot, MD, PhD^20*, Lianqing Zheng, PhD^20*, Remus Vezan, MD, PhD²⁰, Zahid Bashir, MBBS^20*, Jenny J. Kim, MD, MS^20*, Rong Chu, PhD^20* and Sattva S. Neelapu, MD²¹

1658 Clinical Experience of Tabelecleucel in Patients with EBV+ Primary (PID) or Acquired Immunodeficiency (AID) Associated Lymphoproliferative Disease: S Nikiforow, MD, PhD¹, Robert Baiocchi, MD, PhD², S Nasta, MD³, W-K Weng, MD, PhD⁴, D Loeb^5*, K M Mahadeo, MD⁶, J Whangbo, MD, PhD¹, P Phuong^7*, W Navarro, MD⁷, L Gamelin^7*, Y Sun, PhD^8*, N Guzman-Becerra^8* and S Prockop, MD⁹

2100 Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access and Commercial Out-of-Specification (OOS) Product: Caron A. Jacobson, MD¹, Frederick L. Locke, MD², David B. Miklos, MD, PhD³, Julie M. Vose, MD, MBA⁴, Yi Lin, MD, PhD⁵, Lihua E Budde, MD, PhD⁶, David G. Maloney, MD, PhD⁷, Samantha Jaglowski, MD, MPH⁸, Peter A. Riedell, MD^9*, Lazaros J. Lekakis, MD^10*, Miguel-Angel Perales, MD¹¹, Jenny J. Kim, MD, MS^12*, Jun Kawashima, MD^12*, Yin Yang, MS^12*, John M. Rossi, MS^12*, Lovely Goyal, PhD^12* and Sattva S. Neelapu, MD¹³

2329 RNA and TCR Sequencing Shed Light on Mechanisms of Treg Suppression in a Murine Model of Acute GvHD: Juliane K. Lohmeyer, MD^1*, Toshihito Hirai, MD, PhD^1,2*, Mustafa Turkoz, PhD^1*, Natalie Koehler, PhD^1,3*, Jeanette Baker^1*, Stephane Buhler, PhD^4*, Jean Villard, MD, PhD^4*, Xuhuai Ji, MD, PhD^5*, Federico Simonetta, MD, PhD^1,6* and Robert S. Negrin, MD⁷

2554 - Clinical Experience of Tabelecleucel in Patients with Life-Threatening Complications of Epstein-Barr Virus Viremia: L Torno, MD^1*, A Dahlberg, MD^2*, Armin Ghobadi, MD³, P Stiff, MD⁴, R Reshef, MD⁵, W-K Weng, MD, PhD⁶, W Navarro, MD⁷, L Gamelin^7*, R Dinavahi^7*, Y Sun, PhD^8*, N Guzman-Becerra^8* and S Prockop, MD⁹

2103 ZUMA-19: A Phase 1/2 Multicenter Study of Lenzilumab Use With Axicabtagene Ciloleucel (Axi‑Cel) in Patients (Pts) With Relapsed or Refractory Large B Cell Lymphoma (R/R LBCL): Saad S. Kenderian, MD¹, Olalekan O. Oluwole, MBBS, MPH², Philip L. McCarthy, MD³, Ran Reshef, MD⁴, Parveen Shiraz, MD⁵, Omar Ahmed, PharmD^6*, John Le Gall, MD, MBA^7*, Myrna Nahas, MD^7*, Lily Tang, PhD^7* and Sattva S. Neelapu, MD⁸

1120 One-Year Follow-up of ZUMA-2, the Multicenter, Registrational Study of KTE-X19 in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Michael Wang, MD¹, Javier Munoz, MD², Andre H. Goy, MD³, Frederick L. Locke, MD⁴, Caron A. Jacobson, MD^5*, Brian T. Hill, MD⁶, John M. Timmerman, MD⁷, Houston Holmes^8*, Samantha Jaglowski, MD, MPH⁹, Ian W. Flinn, MD, PhD¹⁰, Peter A. McSweeney, MD^11*, David B. Miklos, MD, PhD¹², John M. Pagel, MD, PhD¹³, Marie José Kersten, MD, PhD¹⁴, Noel Milpied^15*, Henry C.H. Fung, MD^16*, Max S. Topp, MD¹⁷, Roch Houot, MD, PhD^18*, Amer Beitinjaneh, MD, MPH, MSc^19*, Weimin Peng, PhD^20*, Lianqing Zheng, PhD^20*, John M. Rossi, MS^20*, Swaminathan Murugappan, MD, PhD^20*, Ioana Kloos, MD^20* and Patrick M. Reagan, MD²¹